Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.86 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.86 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.86 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.77 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.73 |
| ▸ | RXRA | P19793 | 6/20 | 0.72 |
| ▸ | RXRB | P28702 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | RXRG | P48443 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228477 | 0.92 | NR4A2 (1.00) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL4059143 | 0.92 | NR4A2 (1.00) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL6830467 | 0.92 | NR4A2 (1.00) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL8134318 | 0.92 | NR4A2 (0.85) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL11603952 | 0.91 | NR4A2 (0.96) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL11273693 | 0.91 | NR4A2 (0.96) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL11603274 | 0.91 | NR4A2 (0.96) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| Hydrochloric Acid SCHEMBL8544438 | 0.91 | NR4A2 (0.96) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL1756343 | 0.90 | NR4A2 (0.81) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B | |
| SCHEMBL5582767 | 0.90 | NR4A2 (0.81) | NR4A2NR4A1NR4A3SRD5A2PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6156774-A | Beta-thiopropionyl-amino acid derivatives and their use as beta-lactamase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-05 | — | — | US | claimed |
| EP-1000024-A1 | MERCAPTOACYLAMINO ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-17 | — | — | EP | claimed |
| EP-0934262-A1 | BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-08-11 | — | — | EP | claimed |
| WO-1999006365-A1 | MERCAPTOACYLAMINO ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-11 | — | — | WO | claimed |
| WO-1998017639-A1 | BETA-THIOPROPIONYL-AMINO ACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1998-04-30 | — | — | WO | claimed |
| EP-4405334-B1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20250002460-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2025-01-02 | — | — | US | disclosed |
| EP-4405334-A1 | SORTILIN INHIBITORS | Sortina Pharma AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| CN-118317947-A | Sortilin inhibitors | 索蒂纳制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024067560-A1 | SULFONAMIDE COMPOUND AND MEDICAL USE THEREOF | 中国药科大学 | 2024-04-04 | — | — | WO | disclosed |
| CN-117682973-A | Sulfonamide compound and medical application thereof | 中国药科大学 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023101595-A1 | SORTILIN INHIBITORS | SORTINA PHARMA AB (SE) | 2023-06-08 | — | — | WO | disclosed |
| WO-1996011201-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| EP-0467721-B1 | Optically active compound having a delta- valerolactone ring and liquid crystal composition containing same | MITSUBISHI RAYON CO (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-5480580-A | COMPOUNDS FOR VISUAL AIDS WITH GOOD STABILITY | MITSUBISHI RAYON COMPANY LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0677039-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
| EP-0467721-A1 | Optically active compound having a delta- valerolactone ring and liquid crystal composition containing same | MITSUBISHI RAYON CO., LTD (JP) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990014235-A1 | HEAT-SENSITIVE RECORD MATERIAL | SMITH & MCLAURIN LIMITED (GB) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002460-A1 | SORTILIN INHIBITORS | SORT1, GRN, SCARB1 | NR4A2 1904/4885NR4A1 2635/4885NR4A3 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.